more interest in "abuse-deterrent" opioid formulations
May 2014
The Zohydro controversy will lead to more interest in "abuse-deterrent" opioid formulations.
Zohydro is the new long-acting hydrocodone for chronic, severe pain. It's controversial because it's NOT an abuse-deterrent formulation...despite concerns about its abuse potential.
Abuse-deterrent formulations aren't required by FDA...but are being promoted in an effort to reduce prescription opioid abuse.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote